Provectus outlines 2023 regulatory path for PV-10 in rare in-transit melanoma, updates pipeline

PROVECTUS BIOPHARMACEUTICALS, INC.

Plans regulatory pathway for PV-10 monotherapy to treat rare in-transit melanoma; cites 56% CR in 121 patients.
Plans Phase 2/3 RCT of PV-10 + immune checkpoint blockade vs. monotherapy for Stage III melanoma; prior data shows 50% CR.
2022 achievements: 6 conference presentations, new patents, expanded research collaborations with Moffitt, Rockefeller, Univ. Calgary.
Discovered PV-10 may act as immune adjuvant in vaccines; synthesized second HX molecule; added Dr. Aru Narendran to SAB.
Received WHO INN name 'rose bengal sodium' for pharmaceutical-grade RBS API; option agreement with Univ. Miami for eye infections.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.